drugset / Trial / NCT07218146
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Timeline
- Start
- 2025-11-30
- Primary completion
- 2028-06-30
- Completion
- 2028-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Amrubicin | Small molecule | — | — |
| Comparator | Lurbinectedin | Other / unclassified | — | — |
| Comparator | Topotecan | Small molecule | — | — |
| Subject | ZL-1310 | Other / unclassified | — | — |